Anticoagulants as Potential SARS-CoV-2 Mpro Inhibitors for COVID-19 Patients: In Vitro, Molecular Docking, Molecular Dynamics, DFT, and SAR Studies.

Simple item page
dc.contributor.authorElmaaty, A
dc.contributor.authorEldehna, W
dc.contributor.authorM, Khattab
dc.contributor.authorKutkat, O
dc.contributor.authorAlnajjar, R
dc.contributor.authorEl-Taweel, A
dc.contributor.authorAl-Rashood, S
dc.contributor.authorAbourehab, M
dc.contributor.authorBinjubair, F
dc.contributor.authorSaleh, M
dc.date.accessioned2022-11-08T08:20:01Z
dc.date.available2022-11-08T08:20:01Z
dc.date.issued2022-11-07
dc.identifier.urihttp://repository.limu.edu.ly/handle/123456789/4549
dc.language.isoenen_US
dc.publisherFaculty of Pharmacyen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.titleAnticoagulants as Potential SARS-CoV-2 Mpro Inhibitors for COVID-19 Patients: In Vitro, Molecular Docking, Molecular Dynamics, DFT, and SAR Studies.en_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijms-23-12235-v5.pdf
Size:
24.12 MB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.74 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Publications